Ikena Oncology, Inc. (IKNA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ikena Oncology, Inc. (IKNA) trades at $17.16 with AI Score 44/100 (Grade C). Ikena Oncology, Inc. is a targeted oncology company focused on developing biomarker-driven medicines. Their lead product candidate, IK-930, targets the Hippo signaling pathway. Market cap: $718.82M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for IKNA: IKNA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IKNA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IKNA: the 1 perspectives are evenly split.
How is this calculated? →Ikena Oncology, Inc. (IKNA) Healthcare & Pipeline Overview
Ikena Oncology, Inc. is a biotechnology company specializing in targeted oncology therapies, particularly those focused on biomarker-defined patient groups. Their lead candidate, IK-930, aims to inhibit the Hippo signaling pathway, positioning them in the competitive and rapidly evolving oncology therapeutics market.
What Is the Investment Thesis for IKNA?
Ikena Oncology presents a notable research candidate within the biotechnology sector, driven by its targeted oncology approach and promising pipeline. The company's lead candidate, IK-930, targeting the Hippo signaling pathway, has the potential to address unmet needs in various cancers. Positive clinical trial data for IK-930 could serve as a significant catalyst, driving investor interest and potentially leading to partnerships or acquisitions. Furthermore, the development of IK-175 and IK-007 diversifies Ikena's pipeline and reduces reliance on a single asset. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from other oncology therapies. With a market cap of $718.82M and a beta of 0.50, Ikena exhibits moderate volatility. Successful execution of its clinical programs and strategic partnerships will be crucial for realizing its long-term value.
Based on FMP financials and quantitative analysis
IKNA Key Highlights
- Market capitalization of $718.82M reflects investor valuation of Ikena Oncology's pipeline and technology.
- Beta of 0.50 indicates lower volatility compared to the broader market, potentially appealing to risk-averse investors.
- Focus on biomarker-defined patient groups aligns with the growing trend of personalized medicine in oncology.
- Development of multiple targeted therapies diversifies risk and expands potential market opportunities.
- Headquartered in Boston, a major biotechnology hub, provides access to talent, resources, and potential partnerships.
Who Are IKNA's Competitors?
IKNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASLN ASLN | $0.60 | -14.27% | $777.12M | 56 |
| CDMO CDMO | $12.49 | +0.00% | $798.90M | 38 |
| CMRX Chimerix, Inc. | $8.54 | +0.00% | $801.08M | 50 |
| EXAI Exscientia plc | $4.84 | +0.00% | $633.18M | 46 |
| ICPT Intercept Pharmaceuticals, Inc. | $19.00 | +0.21% | $794.69M | 51 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IKNA's Key Strengths?
- Targeted oncology approach.
- Promising pipeline of drug candidates.
- Focus on biomarker-defined patient groups.
- Experienced management team.
What Are IKNA's Weaknesses?
- Limited financial resources.
- Dependence on clinical trial outcomes.
- Small number of employees.
- No currently marketed products.
What Could Drive IKNA Stock Higher?
- Clinical trial results for IK-930 in Hippo pathway-driven cancers.
- Initiation of clinical trials for ERK5 inhibitor program.
- Advancement of IK-175 and IK-007 through clinical development.
- Potential for strategic partnerships and collaborations.
- Expansion of pipeline through internal research and development.
What Are the Key Risks for IKNA?
- Negative return on equity (-35.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for lead drug candidates.
- Regulatory delays or rejection of drug approvals.
- Competition from other oncology therapies.
- Dependence on securing additional funding.
- Intellectual property challenges and patent expirations.
What Are the Growth Opportunities for IKNA?
- Expansion of IK-930 into additional cancer types: IK-930, Ikena's lead candidate, targets the Hippo signaling pathway. Investigating its efficacy in other cancer types beyond the current focus could significantly expand its market potential. The Hippo pathway is implicated in various cancers, presenting opportunities for broader application. Successful clinical trials in additional indications could drive substantial revenue growth. This expansion could be pursued over the next 3-5 years.
- Advancement of ERK5 inhibitor program: Ikena's small molecule inhibitor program against ERK5 in the RAS signaling pathway represents another growth opportunity. The RAS pathway is frequently mutated in cancer, making it a valuable therapeutic target. Successful development of an ERK5 inhibitor could address a significant unmet need in RAS-driven cancers. This program is in earlier stages of development, with potential clinical trials in the next 2-3 years.
- Strategic partnerships and collaborations: Collaborating with larger pharmaceutical companies or research institutions could accelerate the development and commercialization of Ikena's pipeline. Partnerships can provide access to funding, expertise, and distribution networks. Strategic alliances could also expand Ikena's research capabilities and broaden its pipeline. These partnerships could be formed in the near term, within the next 1-2 years.
- Development of IK-175 for additional indications: IK-175, an oral inhibitor of the aryl hydrocarbon receptor (AhR), has potential applications beyond its initial target indication. Exploring its efficacy in other diseases or cancer types could expand its market opportunity. The AhR pathway is involved in various biological processes, suggesting potential for broader therapeutic use. This expansion could be pursued over the next 3-5 years.
- Commercialization of IK-007 for microsatellite stable colorectal cancer: IK-007, an oral selective EP4 receptor antagonist, is being developed for the treatment of microsatellite stable colorectal cancer. Successful commercialization of IK-007 could generate significant revenue. Colorectal cancer is a major global health burden, and new therapies are needed to improve patient outcomes. The timeline for commercialization depends on clinical trial results and regulatory approvals, potentially within the next 3-4 years.
What Opportunities Does IKNA Have?
- Expansion into new cancer indications.
- Strategic partnerships with larger companies.
- Advancements in personalized medicine.
- Increasing demand for targeted therapies.
What Threats Does IKNA Face?
- Competition from established pharmaceutical companies.
- Clinical trial failures.
- Regulatory hurdles.
- Patent expirations.
What Are IKNA's Competitive Advantages?
- Proprietary targeted therapies.
- Strong intellectual property protection (patents).
- Expertise in biomarker-driven drug development.
- Focus on specific unmet needs in oncology.
What Does IKNA Do?
Ikena Oncology, Inc., founded in 2016 and headquartered in Boston, Massachusetts, is a targeted oncology company dedicated to pioneering innovative medicines for patients with unmet needs. The company focuses on developing therapies that are tailored to specific biomarker-defined patient groups, aiming to improve treatment outcomes and patient lives. Ikena's lead product candidate is IK-930, an oral small molecule inhibitor targeting the transcriptional enhanced associate domain (TEAD), a transcription factor in the Hippo signaling pathway. This pathway is implicated in various cancers, making it a promising target for therapeutic intervention. Beyond IK-930, Ikena is also advancing a small molecule inhibitor program against ERK5 in the RAS signaling pathway, a critical pathway in cancer development and progression. Additionally, the company is developing IK-175, an oral inhibitor of the aryl hydrocarbon receptor (AhR), and IK-007, an oral selective EP4 receptor antagonist designed for the treatment of microsatellite stable colorectal cancer. These programs reflect Ikena's commitment to addressing a range of cancer types with targeted therapies. The company's strategy involves identifying and developing therapies that can selectively target cancer cells based on their unique molecular characteristics, with the goal of maximizing efficacy and minimizing side effects.
What Products and Services Does IKNA Offer?
- Develop targeted oncology therapies for biomarker-defined patient groups.
- Focus on unmet needs in cancer treatment.
- Develop oral small molecule inhibitors.
- Target the Hippo signaling pathway with IK-930.
- Develop inhibitors against ERK5 in the RAS signaling pathway.
- Develop IK-175, an oral inhibitor of the aryl hydrocarbon receptor (AhR).
- Develop IK-007, an oral selective EP4 receptor antagonist for colorectal cancer.
How Does IKNA Make Money?
- Develop and commercialize targeted oncology therapies.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Generate revenue through sales of approved therapies.
- Secure funding through venture capital, public offerings, and partnerships.
What Industry Does IKNA Operate In?
Ikena Oncology operates within the biotechnology industry, specifically focusing on oncology therapeutics. The oncology market is experiencing substantial growth, driven by an aging population, increasing cancer incidence, and advancements in targeted therapies. The competitive landscape is crowded, with numerous companies developing novel cancer treatments. Ikena's focus on biomarker-defined patient groups and targeted therapies positions it within the personalized medicine segment, which is gaining traction due to its potential for improved efficacy and reduced side effects. The company faces competition from established pharmaceutical companies and other biotechnology firms, including those developing therapies targeting similar pathways.
Who Are IKNA's Key Customers?
- Patients with cancer.
- Oncologists and other healthcare professionals.
- Hospitals and cancer treatment centers.
- Pharmaceutical companies (potential partners or acquirers).
ROE -35%Key Financial Metrics
Return on equity for Ikena Oncology, Inc. stands at -35.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -78.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 18.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -68.1%, the inverse of the P/E and a quick read on earnings relative to price.
How Ikena Oncology, Inc. Is Valued
Ikena Oncology, Inc. carries a market capitalization of $718.82M, placing it in the small-cap category. Relative to its peer group, IKNA's quantitative score of 44/100 is roughly in line with the peer average of 48/100.
F-Score 2/9Financial Health
Ikena Oncology, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 31.07 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Ikena Oncology, Inc. revenue of about $3.5M for fiscal 2026, with EPS near $-0.75.
Net buyingInsider Activity
The most recent 12 insider filings for Ikena Oncology, Inc. break down as 0 sales and 12 purchases. On net that is roughly 14.0M shares acquired (about $7.3M) — insiders putting money in tends to read as conviction.
IKNA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Targeted oncology approach.
- Promising pipeline of drug candidates.
- Focus on biomarker-defined patient groups.
- Experienced management team.
Bear Case
- Limited financial resources.
- Dependence on clinical trial outcomes.
- Small number of employees.
- No currently marketed products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
IKNA Latest News
No recent news available for IKNA.
IKNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IKNA.
Price Targets
Wall Street price target analysis for IKNA.
IKNA MoonshotScore
What does this score mean?
The MoonshotScore rates IKNA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mark Manfredi
CEO
Mark Manfredi serves as the Chief Executive Officer of Ikena Oncology, managing a team of 10 employees. His background includes extensive experience in the biotechnology and pharmaceutical industries, with a focus on oncology drug development. Prior to joining Ikena, Manfredi held leadership positions at various biotech companies, where he oversaw the development and commercialization of innovative therapies. His expertise spans drug discovery, clinical development, and business strategy. Manfredi's experience positions him to lead Ikena Oncology in its mission to develop targeted therapies for cancer patients.
Track Record: Under Mark Manfredi's leadership, Ikena Oncology has advanced its pipeline of targeted oncology therapies, including IK-930, IK-175, and IK-007. He has overseen the initiation and execution of clinical trials, as well as the expansion of the company's research and development programs. Manfredi has also been instrumental in securing funding and establishing strategic partnerships to support Ikena's growth. His leadership has been focused on driving innovation and delivering value to patients and shareholders.
What Investors Ask About Ikena Oncology, Inc. (IKNA) — Healthcare
What does Ikena Oncology, Inc. do?
Ikena Oncology, Inc. is a targeted oncology company focused on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. The company's lead product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), a transcription factor in the Hippo signaling pathway. Ikena is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway, as well as IK-175, an oral inhibitor of the aryl hydrocarbon receptor (AhR), and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company aims to improve treatment outcomes for cancer patients by developing therapies that selectively target cancer cells based on their unique molecular characteristics.
What are the main risks for IKNA?
The main risks for Ikena Oncology include the potential for clinical trial failures, regulatory hurdles, and competition from other oncology therapies. The company's success depends on the successful development and commercialization of its pipeline of drug candidates, which is subject to inherent risks and uncertainties. Securing additional funding is also a critical risk, as the company currently has limited financial resources. Additionally, intellectual property challenges and patent expirations could pose a threat to Ikena's competitive position.
How does Ikena Oncology, Inc. navigate regulatory approval processes?
Ikena Oncology navigates regulatory approval processes by adhering to stringent guidelines set by regulatory agencies such as the FDA in the United States. The company's strategy includes comprehensive preclinical studies, well-designed clinical trials, and proactive communication with regulatory authorities. Ikena's regulatory track record is still developing as it advances its pipeline candidates through clinical development. The company's compliance strategy focuses on maintaining high standards of data integrity, patient safety, and ethical conduct throughout the drug development process.
How does Ikena Oncology, Inc. manage patent expiration risks?
Ikena Oncology manages patent expiration risks through a multi-faceted approach that includes actively monitoring its patent portfolio, pursuing patent extensions where possible, and developing new innovations to maintain a competitive edge. The company's patent cliff exposure is currently limited as its lead product candidates are still in early stages of development. However, Ikena's lifecycle management strategies involve exploring new formulations, indications, and combinations to extend the exclusivity of its therapies beyond the initial patent term. The company also invests in research and development to create new intellectual property and stay ahead of biosimilar competition.
What are the key factors to evaluate for IKNA?
Ikena Oncology, Inc. (IKNA) holds an AI score of 44/100 (low). Not financial advice.
How frequently does IKNA data refresh on this page?
IKNA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IKNA's recent stock price performance?
Ikena Oncology, Inc. (IKNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Targeted oncology approach. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IKNA overvalued or undervalued right now?
Valuing Ikena Oncology, Inc. (IKNA) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending may provide further insights.
- Financial data is limited and may not reflect the most current information.